Similar articles

• Cabergoline. A review of its pharmacological properties and therapeutic potential in the treatment of hyperprolactinaemia and inhibition of lactation.

  Rains CP, Bryson HM, Fitton A. Rains CP, et al. Drugs. 1995 Feb;49(2):255-79. doi: 10.2165/00003495-199549020-00009. Drugs. 1995. PMID: 7729332 Review.
• [Possibilities and limits of non-hormonal therapy of the menopausal syndrome].

  Piccione E, Sesti F, Manna C. Piccione E, et al. Clin Ter. 1984 Nov 30;111(4):359-65. Clin Ter. 1984. PMID: 6396027 Review. Italian. No abstract available.
• [Modifications of the incretory pituitary response of prolactin to sulpiride after treatment with bromocryptin].

  Gianrossi R, Gallamini A, Nizzo MC, Murialdo G, Peirano L. Gianrossi R, et al. Boll Soc Ital Biol Sper. 1976 Oct 15;52(19):1568-71. Boll Soc Ital Biol Sper. 1976. PMID: 1037380 Italian. No abstract available.
• Stimulating action of sulpiride and pimozide on prolactin release. Effect on bromocriptine, L-dopa and metergoline administration.

  Delitala G. Delitala G. Acta Endocrinol (Copenh). 1977 Oct;86(2):251-6. doi: 10.1530/acta.0.0860251. Acta Endocrinol (Copenh). 1977. PMID: 578618
• Interaction of sulfpride and ergot derivatives on rat brain DOPAC concentration and prolactin secretion in vivo.

  Hofmann M, Battaini F, Tonon G, Trabucchi M, Spano P. Hofmann M, et al. Eur J Pharmacol. 1979 Jun;56(1-2):15-20. doi: 10.1016/0014-2999(79)90427-8. Eur J Pharmacol. 1979. PMID: 467503